Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Terminated Not applicable Interventional

Safety Study of Plasma Treatment System to Treat Back Acne

NCT01662349
View directory record Official record
Conditions
Acne Vulgaris
Interventions
MOE Antimicrobial Plasma Treatment System
Device
Lead sponsor
Moe Medical Devices
Industry
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Treatment for Moderate to Severe Acne

NCT01206348
View directory record Official record
Conditions
Acne
Interventions
Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years to 30 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Santa Monica, California • Hockessin, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 30, 2026, 8:38 PM EDT
Completed No phase listed Observational

Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA

NCT03039634
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Not listed
Lead sponsor
Sienna Labs
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Santa Monica, California • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT04015375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd), ACZONE® (dapsone) gel, 7.5% (Allergan, INC.), Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)
Drug · Other
Lead sponsor
Torrent Pharmaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
11
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 30, 2026, 8:38 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

NCT05891795
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clascoterone 1% Top Cream, Vehicle
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 8:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris

NCT04596748
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
13 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

NCT02293018
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.75% (w/w) MTC896 Gel Once Daily, 0.75% (w/w) MTC896 Gel Twice Daily, 1.5% (w/w) MTC896 Gel Once Daily
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 30, 2026, 8:38 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Novel Combination Oral Agent to Treat Acne Vulgaris

NCT01301586
View directory record Official record
Conditions
ACNE VULGARIS
Interventions
Doxycycline and S-equol, Doxycycline
Drug
Lead sponsor
Nexgen Dermatologics, Inc.
Industry
Eligibility
13 Years to 60 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Rolling Hills Estates, California • Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 30, 2026, 8:38 PM EDT
Not listed Phase 4 Interventional

Efficacy & Safety of Clindamycin and Tretinoin in Acne

NCT01111994
View directory record Official record
Conditions
Acne
Interventions
Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Mitchellville, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2010 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

NCT00722761
View directory record Official record
Conditions
Acne Vulgaris
Interventions
drospirenone and ethinyl estradiol, Placebo tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 30, 2026, 8:38 PM EDT
Recruiting Phase 3 Interventional

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

NCT07335588
View directory record Official record
Conditions
Lichen Sclerosus
Interventions
Delgocitinib, Cream Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

NCT03427554
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

NCT03664739
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDp-120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
608 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
25
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 30, 2026, 8:38 PM EDT
Terminated No phase listed Observational Results available

Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population

NCT00964119
View directory record Official record
Conditions
Acne
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02566369
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene) 50μg/g cream, Placebo cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
86
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 30, 2026, 8:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome

NCT05271487
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Multi-Step Botanical Skin Care Regimen
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
15 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications

NCT01015638
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and BPO 5% gel, Clindamycin phosphate and benzoyl peroxide 2.5% gel.
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 1 Interventional

Timolol for the Treatment of Acne and Rosacea

NCT02774590
View directory record Official record
Conditions
Acne Vulgaris, Rosacea
Interventions
Timolol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Not applicable Interventional Results available

Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne

NCT01629797
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Educational script on Acne
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 30, 2026, 8:38 PM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 8:38 PM EDT
Not listed No phase listed Observational

Design and Validation of a New Assessment Tool for Lichen Planopilaris

NCT03082560
View directory record Official record
Conditions
Lichen Planopilaris of Scalp, Lichen Plano-Pilaris, Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Boston Grade of Activity in Lichen Planopilaris
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of a New Drug Treatment for Acne

NCT01326780
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA, Vehicle control
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
San Diego, California • Colorado Springs, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 8:38 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

NCT06989840
View directory record Official record
Conditions
Acne
Interventions
TVB-3567, Placebo
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne

NCT00594425
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Methyl aminolevulinate (MAL) PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
15 Years to 40 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
San Diego, California • Vallejo, California • Naperville, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 30, 2026, 8:38 PM EDT